



# ESMO 2018 presidential symposium— IMpassion130: atezolizumab+nab- paclitaxel in triple-negative breast cancer

Peter Schmid

**To cite:** Schmid P. ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer. *ESMO Open* 2018;3:e000453. doi:10.1136/esmoopen-2018-000453

Received 4 October 2018  
Accepted 4 October 2018

© Author (s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ on behalf of the European Society for Medical Oncology.

Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London, England

#### Correspondence to

Peter Schmid; p.schmid@qmul.ac.uk

[Click here to listen to the Podcast](#)

The IMpassion130 trial was a global, randomised, double-blind, phase III study of atezolizumab+nab-paclitaxel versus placebo+nab-paclitaxel in patients with treatment naive locally advanced or metastatic triple-negative breast cancer. Here, progression-free survival was statistically significantly longer in patients treated with the combination of atezolizumab+nab-paclitaxel compared with placebo+nab-paclitaxel. The side effect profile was favourable as no unexpected toxicities were observed in the intervention compared with the control arm. In the current podcast, PS provides insight on the response rate and the preliminary survival analysis of IMpassion130. Further possible biomarkers and the impact of the results on

the treatment standard in breast cancer are discussed.

**Funding** The author has not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient consent** Not required.

**Provenance and peer review** Not commissioned; internally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, any changes made are indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.